Search Results

Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon 3.0 with StimGuide Pro.

Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA has cleared the Horizon 3.0 (with or without StimGuide+) and E-z Cool Coil to treat adult patients diagnosed with Obsessive Compulsive Disorder (OCD) as well as Major Depressive Disorder (MDD).

Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded 510K clearance for Horizon 3.0. Designed specifically for the clinical setting, Horizon 3.0 offers enhanced workflows with navigated TMS and analytics.

Magstim, the global leader in Transcranial Magnetic Stimulation (TMS), today announced an agreement to acquire the product portfolio of Electrical Geodesics, Inc. (EGI) from Royal Philips (NYSE:PHG; AEX: PHIA), a global leader in health technology.

Magstim®TMS has launched the very first Transcranial Magnetic Stimulation navigation system specifically developed for the clinical market.

The Horizon ® system was designed to offer more versatility in one system, and more treatment options for patients.

HORIZON TMS Therapy is a proven, safe and cost-effective treatment for MDD.